« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | |
| Code Name: | IPH 2101 (anti-KIR) |
| Company: | Innate Pharma |
| FDA Clinical Phase: | 1/2 |
Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune …
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a …
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is …
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Triphase Research and Development I Corp |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) (news articles) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the …
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Panobinostat (news articles), which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, …
| Brand Name: | Afinitor |
| Generic Name: | everolimus |
| Code Name: | RAD001 |
| Company: | Novartis |
| FDA Clinical Phase: | 1/2 |
Description:
Afinitor was approved by the FDA in March 2009 for the …